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Introduction
The following discussion highlights recent and in intervention such as exposure molecular epidemiologic research on the reduction and chemoprevention.
use of biologic markers in the prevention Effects of Environmental of environmental carcinogenesis and repro-Effect s o n Humanm en t h ductive toxicity. The research explores the Exposures on Human Heafth potential of molecular epidemiology as an Clear effects of environmental exposures early warning system of adverse effects, as a on biomarkers have been seen in active and means of understanding variability in risk, passive smokers, workers, and others exposed to ambient pollution and carcinogens in the diet. For example, serial samples from 40 heavy smokers (>1 pack/day for >1 year) enrolled in a smoking cessation program were assayed for cotinine, polycyclic aromatic hydrocarbon (PAH)-DNA, 4-aminobiphenyl-hemoglobin (4-ABP-Hb) adducts, and glycophorin A (GPA) mutations. Blood samples were taken while smoking and at 10 weeks and 8 and 14 months after quitting. Cotinine was used to assess compliance with the cessation protocol. A significant reduction in mean PAH-DNA and 4-ABP-Hb adducts was observed following cessation in all persons who were cotinine-verified quitters (<25ng/ml) for .8 months (p<0.05).
Neither GPA N/0 nor GPA N/N mutations were significantly reduced following smoking cessation, but results are limited by the small number (n = 18) of heterozygous individuals studied (1 Among infants with induced placental CYPIAI, adducts in infant cord blood were inversely correlated with the levels of CYPlAI induction/activity (2) . Adduct levels in infant cord leukocytes were higher than adduct levels in paired maternal samples, both in the total cohort (7.9 ± 9.9 vs 5.9 ± 8.2 per 108 nucleotides) and after stratification by placental CYPIAI induction. These results indicate that the placenta, by metabolizing PAH, decreases their transfer to the fetus and suggest increased susceptibility of the developing fetus to PAH-DNA adduct formation. The higher adduct levels in newborn samples compared to paired maternal samples is particularly striking, given evidence from experimental bioassays that transplacental exposure to PAH is at least an order of magnitude lower than maternal exposure (4, 5) .
In addition to using biomarkers as environmental dosimeters, several studies have shown associations between specific biomarkers and reproductive effects (6) . In a prior study, a highly significant association was found between decreased birth weight and the level of smoking-related adducts in placental tissue collected from 30 smoking mothers (7) . By contrast, no association was seen between decreased birth weight and either intensity of smoking exposure assessed by questionnaire data or biochemical measures of smoking exposure (cotinine, thiocyanate, and carboxyhemoglobin). In the study of Polish mothers and newborns described above, an inverse association was seen between infant cord PAH-DNA adduct levels (as a biologically relevant dosimeter of fetal exposure) and the development of the infant. The not correlated in either year. These results suggest a molecular link between somatic gene mutation and PAHs (9).
In the above-mentioned study of heavy smokers, the substantial reduction (50-75%) in PAH-DNA and 4-ABP-Hb adduct levels after quitting smoking indicates that these carcinogen adducts provide molecular evidence of the benefits of smoking cessation (1) . The biomarkers can therefore be useful in compliance ascertainment and feedback.
Chemoprevention
Biologic markers already play an important role in the evaluation of chemopreventive agents, specifically in Phase II trials (10) (11) (12) . The most commonly used genetic markers in current trials involving lung and upper aerodigestive tract tumors include micronuclei, DNA content, genetic alteration in oncogenes, and markers of proliferation, growth regulation and differentiation (12) .
Our research also suggests that additional earlier biomarkers such as carcinogen-DNA adducts can be useful in intervention studies of exposed or at risk populations. Several recent studies have examined whether baseline levels of micronutrients (vitamins C, E, ,-carotene, or retinol) in the serum of persons who have not been treated with chemoprevention are inversely related to genetic damage (9, 13) . In a cross-sectional study of 63 heavy smokers, the serum concentrations of a-tocopherol (cholesterol-adjusted), ascorbic acid, 1-carotene, and retinol were evaluated in relationship to the levels of PAH-DNA adducts in lymphocytes measured in the same individuals (14) . All of the participants were current smokers, and 90% had smoked one or more packs per day for at least 10 years. A significant inverse correlation was found between serum a-tocopherol and PAH-DNA adducts. Although the relationship was not statistically significant, serum ascorbic acid, 1-carotene, and retinol were inversely correlated with adducts.
In the smoking cessation cohort described above, both a-tocopherol and retinol were inversely correlated with PAH-DNA adducts at baseline while subjects were smoking and in follow-up samples after cessation. In addition, the GSTMI genotype modified the relationship between DNA adducts and a-tocopherol. Indicating an interaction between two susceptibility factors, a-tocopherol had a strong inverse effect in subjects lacking the GSTMI gene, whereas in subjects with the gene, there was no signficant association (unpublished data).
Once validated, biologic markers can be incorporated into a wide variety of intervention and chemoprevention studies of smokers, workers, and other populations at high risk of disease.
